Anti-TFPI Single-Domain Antibodies: Novel Rebalancing Therapies for Hemophilia and Other Rare Bleeding Disorders
Thrombosis and Haemostasis · 30.06.2026
DOI: 10.1055/a-2894-0856 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 30.06.2026. Verfasst von Claire Auditeau und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hémostase Inflammation Thrombose HITh U1176, Université Paris-Saclay, INSERM, Ile de France, France, Le Kremlin-Bicetre.
Abstract (Originalsprache)
Background
Tissue factor pathway inhibitor (TFPI) is an important determinant of thrombin generation in patients with deficiency in factor (F)VIII, FIX, and FXI. As such, anti-TFPI monoclonal antibodies such as concizumab have been developed to treat hemophilia A (HA) and B (HB).
Aim
The objective of this study is to generate single-domain antibodies (sdAbs) as a novel class of pharmacological agents blocking TFPI and increasing thrombin generation in the plasma of patients with severe HA, HB, and FXI deficiency.
Methods
A large synthetic library of sdAbs was generated and selected by phage-display on recombinant human TFPIα (rhTFPIα). Anti-TFPI sdAbs were screened on their ability to promote thrombin generation. Their binding to the Kunitz (K1, K2, K3) domains of TFPIα were measured by enzyme-linked immunosorbent assay. Their effects on the inhibitory activity of rhTFPIα toward FXa and TF/FVIIa complex were tested in purified systems. Thrombin generation was measured on plasmas from patients with severe HA, HB, or FXI-deficiency spiked with the anti-TFPI sdAbs.
Results
A total of 14 out of 188 screened sdAbs specifically bound to rhTFPIα, and two of them (26E5 and 26E8) targeted the K1 domain of TFPI and increased thrombin generation in the plasma of patients with HA. Both sdAbs impaired the ability of rhTFPIα to inhibit FXa and TF/FVIIa, in the absence and presence of their physiological modulators (protein S and FXa, respectively). These sdAbs efficiently increased thrombin generation in HB and FXI-deficient plasmas.
Conclusion
Our large synthetic library could be used for readily generating diverse and functionally relevant anti-TFPI sdAbs that may be therapeutically attractive.
Autor:innen und Institutionen
- Hémostase Inflammation Thrombose HITh U1176, Université Paris-Saclay, INSERM, Ile de France, France, Le Kremlin-Bicetre.
- Hôpital Necker Enfants Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Service d'Hématologie Biologique, France, Paris.
- Inovarion SAS, Île-de-France, France, Paris.
- Maastricht University, Biochemistry, LI, Netherlands, Maastricht.
- Centre Hospitalier Régional et Universitaire (CHRU) de Nancy, Grand Est, France, Nancy.
ORCID-Profile: Claire Auditeau, Elsa P Bianchini, Olivier D Christophe
Zitieren
APA
Auditeau, C., Bianchini, E. P., Peyron, I., Ruty, A., Saenjamsai, P., Khamari, M., Hackeng, T. M., Christophe, O. D., Denis, C. V., Borgel, D., Lenting, P. J., & Saller, F. (2026). Anti-TFPI Single-Domain Antibodies: Novel Rebalancing Therapies for Hemophilia and Other Rare Bleeding Disorders. Thrombosis and Haemostasis. https://doi.org/10.1055/a-2894-0856
Vancouver
Auditeau C, Bianchini EP, Peyron I, Ruty A, Saenjamsai P, Khamari M, et al. Anti-TFPI Single-Domain Antibodies: Novel Rebalancing Therapies for Hemophilia and Other Rare Bleeding Disorders. Thrombosis and Haemostasis. 2026. doi:10.1055/a-2894-0856
BibTeX
@article{Auditeau2026,
author = {Auditeau, Claire and Bianchini, Elsa P and Peyron, Ivan and Ruty, Andréa and Saenjamsai, Pradtahna and Khamari, Mariem and Hackeng, Tilman M and Christophe, Olivier D and Denis, Cecile V and Borgel, Delphine and Lenting, Peter J and Saller, FranÇois},
title = {Anti-TFPI Single-Domain Antibodies: Novel Rebalancing Therapies for Hemophilia and Other Rare Bleeding Disorders},
journal = {Thrombosis and Haemostasis},
year = {2026},
doi = {10.1055/a-2894-0856}
}
EUVIMED